Abstract
Previously healthy infants less than 6 months of age with severe respiratory syncytial virus bronchiolitis who required hospitalization were identified from hospital records. Infants had been treated either conservatively (control group, n = 19) or with ribavirin added to conservative management (study group, n = 22). All infants underwent a 1-year follow-up after the initial illness. There was a significant reduction in the prevalence of reactive airway disease in the group treated with ribavirin (P < 0.05) compared with the control group, both in terms of the proportion of patients developing airway reactivity (59% vs. 89%) and the number of episodes of reactive airway disease (31 vs. 70). Our data suggest that ribavirin reduces the prevalence of airway reactivity.
MeSH terms
-
Albuterol / administration & dosage
-
Albuterol / therapeutic use
-
Antiviral Agents / therapeutic use*
-
Asthma / prevention & control
-
Bronchial Hyperreactivity / prevention & control*
-
Bronchiolitis / drug therapy
-
Bronchiolitis / virology*
-
Bronchodilator Agents / administration & dosage
-
Bronchodilator Agents / therapeutic use
-
Follow-Up Studies
-
Glucocorticoids / administration & dosage
-
Glucocorticoids / therapeutic use
-
Hospitalization
-
Humans
-
Infant
-
Infant, Newborn
-
Methylprednisolone / administration & dosage
-
Methylprednisolone / therapeutic use
-
Oxygen Inhalation Therapy
-
Prednisone / administration & dosage
-
Prednisone / therapeutic use
-
Prevalence
-
Respiratory Sounds / drug effects
-
Respiratory Syncytial Virus Infections / drug therapy*
-
Respiratory Syncytial Virus, Human*
-
Retrospective Studies
-
Ribavirin / therapeutic use*
Substances
-
Antiviral Agents
-
Bronchodilator Agents
-
Glucocorticoids
-
Ribavirin
-
Albuterol
-
Prednisone
-
Methylprednisolone